Oridonin acts as a novel senolytic by targeting glutathione S-transferases to activate the ROS-p38 signaling axis in senescent cells

  • Chem Commun (Camb). 2022 Nov 29;58(95):13250-13253. doi: 10.1039/d2cc05278d.
Ying Zhang  1 ,  Qianyu Zhang  2 ,  Zheng Chu  1 ,  Lin Chen  1 ,  Jiayun Chen  1 ,  Yang Yang  1 ,  Huan Tang  1 ,  Guangqing Cheng  1 ,  Ang Ma  1 ,  Ying Zhang  1 ,  Chen Wang  1 ,  Peng Gao  1 ,  Fei Xia  1 ,  Qiuyan Guo  1 ,  Qiaoli Shi  1 ,  Guang Han  2 ,  Jigang Wang  1  3 ,  Yinhua Zhu  1
Affiliations
  • 1. Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. [email protected].
  • 2. Pharmaceutical College, Henan University, Kaifeng, 75004, China. [email protected].
  • 3. Department of Nephrology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen 518020, Guangdong, China.
PMID: 36367053 DOI: 10.1039/d2cc05278d
Abstract

Most of the known senolytics are anti-cancer drugs or their derivative molecules. However, senolytics derived from the active ingredients of traditional Chinese medicine (TCM) are rarely reported. Here, we identified oridonin as a novel senolytic and further revealed that it might target a class of glutathione S-transferases to activate ROS-p38 signaling and induce Apoptosis in senescent cells.

Products